Tirzepatide
Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
Prescription dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist used for type 2 diabetes and chronic weight management when prescribed under an FDA-approved label.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
Prescription dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist used for type 2 diabetes and chronic weight management when prescribed under an FDA-approved label. NutriStack rates the supporting evidence as strong. Common adult dosing is 2.5-15 mg subcutaneous injection once weekly, titrated per prescribing information, though a prescriber sets the actual dose. This profile indexes 5 sources.
- Nausea
- Vomiting
- Diarrhea
- Personal or family history of medullary thyroid carcinoma (MTC)4
- Multiple endocrine neoplasia syndrome type 2 (MEN 2)
The bottom line
Evidence rating strong. Most-documented uses: lowers hba1c in type 2 diabetes, substantial weight loss in chronic weight-management trials, once-weekly subcutaneous administration. 5 sources indexed (2021–2026), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
Activates GIP and GLP-1 receptors, increasing glucose-dependent insulin secretion, lowering glucagon, slowing gastric emptying, reducing appetite, and improving glycemic control and body weight in indicated populations.3
Dosing & protocol.
Subcutaneous prescription medication; food timing is not the primary driver of exposure.
Full safety detail.
Side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain or dyspepsia
- Injection-site reactions
- Hypoglycemia when combined with insulin or sulfonylureas
- Pancreatitis and gallbladder disease have been reported
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Randomized controlled trials
3- 1Tirzepatide Once Weekly for the Treatment of ObesitySource linkedPMIDJastreboff AM et al. · N Engl J Med · 2022
SURMOUNT-1 showed large mean body-weight reductions with weekly tirzepatide versus placebo.
- 2Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 DiabetesSource linkedPMIDFrias JP et al. · N Engl J Med · 2021
SURPASS-2 found greater HbA1c and body-weight reductions with tirzepatide than semaglutide 1 mg in adults with type 2 diabetes.
- 3Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4)Source linkedPMIDDel Prato S et al. · Lancet · 2021
SURPASS-4 compared tirzepatide with insulin glargine in adults with type 2 diabetes and increased cardiovascular risk.
Reference material
2- 4ZEPBOUND (tirzepatide) prescribing informationSource linkedURLDailyMed / U.S. National Library of Medicine · DailyMed · 2026
Labeling includes a boxed warning about thyroid C-cell tumors in rats and contraindication with personal/family history of MTC or MEN 2.
- 5FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight LossSource linkedURLU.S. Food and Drug Administration · FDA · 2026
FDA warns that unapproved GLP-1 versions, including semaglutide and tirzepatide products, do not undergo FDA review for safety, effectiveness, or quality.
Common questions.
Quick answers about Tirzepatide, drawn from the data on this page.
What is Tirzepatide?
Prescription dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist used for type 2 diabetes and chronic weight management when prescribed under an FDA-approved label.
What is Tirzepatide used for?
Commonly cited benefits of Tirzepatide include: Lowers HbA1c in type 2 diabetes; Substantial weight loss in chronic weight-management trials; Once-weekly subcutaneous administration; Low intrinsic hypoglycemia risk as monotherapy, but risk rises with insulin or sulfonylureas. NutriStack rates the overall evidence as strong.
What is a typical dose of Tirzepatide?
A typical adult dose of Tirzepatide is 2.5-15 mg subcutaneous injection once weekly, titrated per prescribing information. The commonly recommended form is FDA-approved prefilled pen or vial/syringe product prescribed by a clinician. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Tirzepatide?
Reported side effects include nausea, vomiting, diarrhea, constipation, abdominal pain or dyspepsia, injection-site reactions. This is educational information; check with a healthcare professional before use.
How strong is the evidence for Tirzepatide?
NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Tirzepatide in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.